Your current location:

Capacity for the Evaluation of Ophthalmology Gene Therapy at KBI

2022-03-11
4434
Kunming, China, March 11, 2022

Retinal eye diseases, such as diabetic retinopathy and age-related macular degeneration, are highly prevalent in the middle-aged and aged population. Retinal gene therapy offers the best hope for the sustained effective treatment of these eye diseases with minimal adverse effects. 


Now KBI has successfully established a technique of subretinal injection in non-human primate (NHP) as shown below. This is very important for the translation of a gene therapy to clinical application because subretinal injection delivers gene therapy to the target location and avoid off-target effects and adverse reactions in other locations.

SRI.jpg

Subretinal injection is an extremely delicate skill and very difficult to operate. By establishing this technique in NHP models of eye diseases, KBI is well positioned to provide pre-clinical evaluations closest to clinical trial on gene therapy for eye diseases in humans.


Contact us if you need more information.

Copyright © 2024 Kunming Biomed International Ltd. All Rights Reserved     |Privacy Policy|Terms of Use|
4571 Boda Road, Chenggong, Kunming, Yunnan, 650500, China